Canagliflozin alleviates pulmonary hypertension by activating PPARγ and inhibiting its S225 phosphorylation.
Li XC, Zhu XY, Wang YY, Tong SL, Chen ZL, Lu ZY, Zhang JH, Song LL, Wang XH, Zhang C, Sun YH, Zhong CY, Su LH, Wang LX, Huang XY.
Li XC, et al. Among authors: chen zl.
Acta Pharmacol Sin. 2024 May 8. doi: 10.1038/s41401-024-01286-9. Online ahead of print.
Acta Pharmacol Sin. 2024.
PMID: 38719955